Item 5.07. Submission of Matters to a Vote of Security Holders.

Sage Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2020. As of April 13, 2020, the record date for the Annual Meeting, there were 51,917,819 outstanding shares of the Company's common stock. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission ("SEC") on April 29, 2020: (i) to elect two directors, Michael F. Cola and Jeffrey M. Jonas, M.D., as Class III directors of the Company to each serve for a three-year term expiring at the Company's annual meeting of stockholders in 2023 and until their successors have been duly elected and qualified, subject to their earlier death, resignation or removal ("Proposal 1"), (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020 ("Proposal 2") and (iii) to hold a nonbinding advisory vote to approve the compensation paid to the Company's named executive officers ("Proposal 3").

The Company's stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for Class III directors as follows:



Class III Director Nominee       For            Withheld        Broker Non-Votes
Michael F. Cola                26,191,095       17,094,011              3,226,045
Jeffrey M. Jonas, M.D.         34,601,726        8,683,380              3,226,045

The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP in Proposal 2. The votes cast at the Annual Meeting were as follows:



   For       Against   Abstain   Broker Non-Votes
46,421,270   80,296     9,585           0

The Company's stockholders approved, on a nonbinding advisory basis, the compensation of the Company's named executive officers in Proposal 3. The votes cast at the Annual Meeting were as follows:

For Against Abstain Broker Non-Votes 26,623,925 16,643,658 17,523 3,226,045

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.



                                   *   *    *

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses